Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J SCHNITZER

Allopathic & Osteopathic Physicians Neuromusculoskeletal Medicine, Sports Medicine

NPI
1588649461
CMS profile
1063101
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$48,294.43

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $29,580.17 38
Noven Therapeutics, LLC $9,117.23 4
PFIZER INC. $4,581.55 2
AstraZeneca UK Limited $2,750.00 1
Eli Lilly and Company $2,265.48 7

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J SCHNITZER

NPI 1588649461 · CMS profile ID 1063101

Allopathic & Osteopathic Physicians / Neuromusculoskeletal Medicine, Sports Medicine

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588649461?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J SCHNITZER, NPI 1588649461, CMS profile ID 1063101. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588649461?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). THOMAS J SCHNITZER, NPI 1588649461, CMS profile ID 1063101. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588649461?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
THOMAS J SCHNITZER, NPI 1588649461, CMS profile ID 1063101, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1588649461?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $48,294.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Noven Therapeutics, LLC $7.5101/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743839493 CMS
Noven Therapeutics, LLC $15.5401/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743839495 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $106,683.73 93
PY2020 $48,294.43 52
PY2021 $83,735.95 15
PY2022 $15,563.90 6
PY2023 $48,233.22 45
PY2024 $18,915.40 30
PY2025 $16,034.18 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,341,406.70 72
PY2024 Recipient $63,988.25 7
PY2024 Principal investigator $1,911,191.09 26
PY2023 Recipient $3,815.02 4
PY2023 Principal investigator $1,115,896.79 20
PY2022 Recipient $27,446.00 11
PY2022 Principal investigator $1,506,717.04 54
PY2021 Recipient $28,110.00 16
PY2021 Principal investigator $1,318,472.61 50
PY2020 Recipient $18,609.00 25
PY2020 Principal investigator $563,051.21 53
PY2019 Recipient $1,012.23 8
PY2019 Principal investigator $852,595.05 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $47,951.32 11/25/2025 Non-covered Recipient Entity
NORTHWESTERN UNIV
Effects of Romosozumab on Bone Health in Women with Spinal Cord Injury and Osteoporosis No dispute reported 06/30/2026 1246645624
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187878773
Principal investigator 1 Eli Lilly and Company $1,093.96 10/28/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187878889
Principal investigator 1 GlaxoSmithKline, LLC. $20,855.57 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165807
Principal investigator 1 Eli Lilly and Company $111.45 08/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187888836
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102126
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106715
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106735
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107958
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163312
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 06/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165832
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102113
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102118
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102132
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102138
Principal investigator 1 GlaxoSmithKline, LLC. $121.28 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102144
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102149
Principal investigator 1 GlaxoSmithKline, LLC. $191.40 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192102155
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106689
Principal investigator 1 GlaxoSmithKline, LLC. $708.68 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106703
Principal investigator 1 GlaxoSmithKline, LLC. $59.40 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106709
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106723
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106728
Principal investigator 1 GlaxoSmithKline, LLC. $422.40 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107934
Principal investigator 1 GlaxoSmithKline, LLC. $363.84 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107946
Principal investigator 1 GlaxoSmithKline, LLC. $238.86 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107951
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107964
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109663
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109679
Principal investigator 1 GlaxoSmithKline, LLC. $921.20 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109692
Principal investigator 1 GlaxoSmithKline, LLC. $250.80 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109697
Principal investigator 1 GlaxoSmithKline, LLC. $472.08 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163292
Principal investigator 1 GlaxoSmithKline, LLC. $121.28 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163301
Principal investigator 1 GlaxoSmithKline, LLC. $406.40 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163305
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163308
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163317
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163321
Principal investigator 1 GlaxoSmithKline, LLC. $191.40 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165802
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165814
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165817
Principal investigator 1 GlaxoSmithKline, LLC. $577.00 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165822
Principal investigator 1 GlaxoSmithKline, LLC. $570.08 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165827
Principal investigator 1 Eli Lilly and Company $103,692.44 03/24/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187890144
Principal investigator 1 GlaxoSmithKline, LLC. $1,225.42 02/24/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192165809
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106696
Principal investigator 1 GlaxoSmithKline, LLC. $7,000.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107928
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107940
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109658
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109671
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109686
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192159594
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192159598
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192163296
Principal investigator 1 Novartis Pharmaceuticals Corporation $178.99 02/10/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis No dispute reported 06/30/2026 1190300683
Principal investigator 1 GlaxoSmithKline, LLC. $2,063.88 02/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192109703
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $122,849.04 02/05/2025 Non-covered Recipient Entity
FEINBERG SCHOOL OF MEDICINE ANESTHESIOLOGY
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124678
Principal investigator 1 Eli Lilly and Company $908.32 01/31/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187890138
Principal investigator 1 Eli Lilly and Company $597.58 01/31/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE (TRIUMPH-4) No dispute reported 06/30/2026 1187890140
Principal investigator 1 GlaxoSmithKline, LLC. $953.71 01/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192106740
Principal investigator 1 Eli Lilly and Company $846,162.00 01/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187886836
Principal investigator 1 GlaxoSmithKline, LLC. $2,450.84 01/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192107921
Principal investigator 1 Eli Lilly and Company $8,313.93 01/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187888560
Principal investigator 1 Eli Lilly and Company $1,484.29 01/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187888828
Principal investigator 1 Eli Lilly and Company $99,620.00 01/21/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE (TRIUMPH-4) No dispute reported 06/30/2026 1187885088
Principal investigator 1 Eli Lilly and Company $112,826.00 01/21/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187886088
Principal investigator 1 Eli Lilly and Company $2,179.09 01/14/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187885086
Principal investigator 1 Eli Lilly and Company $1,217.51 01/09/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187887356
Principal investigator 1 Eli Lilly and Company $178,309.00 01/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187887352
Principal investigator 1 Eli Lilly and Company $106,512.00 01/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187887354
Principal investigator 1 Eli Lilly and Company $182,571.00 01/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) No dispute reported 06/30/2026 1187888444
Principal investigator 1 Eli Lilly and Company $236,402.00 01/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187888826
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $222,342.34 01/01/2025 Non-covered Recipient Entity
FEINBERG SCHOOL OF MEDICINE ANESTHESIOLOGY
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123760